BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...Capital, Bluebird Ventures, Narya Capital, existing investor Amplo, Paul Manning, Asia Alpha, seed round leader Transhuman Capital...
...QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, Asia Alpha and Transhuman Capital...
Items per page:
1 - 1 of 1
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...Capital, Bluebird Ventures, Narya Capital, existing investor Amplo, Paul Manning, Asia Alpha, seed round leader Transhuman Capital...
...QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, Asia Alpha and Transhuman Capital...
Items per page:
1 - 1 of 1